Share This Page
Drug Price Trends for GUAIFENESN-DM
✉ Email this page to a colleague
Average Pharmacy Cost for GUAIFENESN-DM
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GUAIFENESN-DM 100-10 MG/5 ML CUP | 81033-0103-50 | 0.40512 | ML | 2025-10-01 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Guaifenesin-DM
What is Guaifenesin-DM?
Guaifenesin-DM is a combination medication containing guaifenesin, an expectorant, and dextromethorphan (DM), a cough suppressant. It is used primarily to treat coughs and chest congestion associated with upper respiratory infections.
Market Overview
Approved Market and Usage
Guaifenesin-DM is broadly available over-the-counter (OTC) in many countries. It is marketed under various brand names, such as Robitussin, Mucinex DM, and Delsym. The OTC segment constitutes approximately 85% of the global Guaifenesin-DM market, with prescription formulations occupying the remaining 15% mainly in regulated markets like Europe.
Market Size (2022-2023)
| Region | Market Value (USD billion) | Year-over-Year Growth (%) |
|---|---|---|
| North America | 1.2 | 4.5 |
| Europe | 0.6 | 3.8 |
| Asia-Pacific | 0.4 | 7.2 |
| Latin America | 0.2 | 2.9 |
| Rest of World | 0.1 | 3.4 |
| Total | 2.5 | 5.0 |
The global Guaifenesin-DM market was valued at approximately USD 2.5 billion in 2022, with a projected compound annual growth rate (CAGR) of 5% through 2027, driven by increasing demand in emerging markets and expanding OTC availability.
Competitive Landscape
Major players include Johnson & Johnson, Reckitt Benckiser, Pfizer, and Perrigo. These firms dominate through brand recognition and extensive distribution channels. Private-label brands account for nearly 15% of the market.
Regulatory Environment
Regulatory frameworks influence market dynamics, especially regarding OTC classification and restrictions. Notably:
- The US FDA permits OTC sales without prescription.
- Certain European countries regulate dosing and packaging.
- Some markets restrict sales of dextromethorphan to prevent misuse, which may impact sales volume.
Price Trends and Projections
Current Price Range (2023)
| Product Type | Price per Unit (USD) | Units per Pack | Pack Price (USD) |
|---|---|---|---|
| OTC Liquid (4 fl oz) | $6.00 - $9.00 | 1 | $6 - $9 |
| OTC Tablets (100 mg, 20) | $4.00 - $7.00 | 20 | $4 - $7 |
| Prescription formulations | $15.00 - $30.00 | N/A | N/A |
Price Drivers
- Manufacturing costs: Slight increases due to raw material inflation.
- Packaging and distribution: Steady costs with some economies of scale.
- Regulatory compliance: Adds costs in certain markets.
- Branding: Well-established brands command premiums up to 20% over generics.
Future Price Projections (2024-2027)
| Year | OTC Pack Price (USD) | Prescription Pack Price (USD) |
|---|---|---|
| 2024 | $6.50 - $10.00 | $16 - $32 |
| 2025 | $6.75 - $10.50 | $17 - $34 |
| 2026 | $7.00 - $11.00 | $18 - $36 |
| 2027 | $7.25 - $11.50 | $19 - $38 |
Prices are expected to rise modestly, primarily driven by inflation and increased regulatory compliance costs.
Market Entry and Competitive Strategies
For new entrants aiming to gain market share:
- Focus on cost-effective manufacturing.
- Leverage direct-to-consumer marketing, especially digital channels.
- Offer competitive pricing with flexible pack sizes.
- Build trust through quality assurance and transparent labeling.
Key Market Growth Factors
- Rising respiratory illnesses globally.
- Growing OTC adoption in developing markets.
- Increased consumer preference for combination cough remedies.
- Expansion of pharmacy chains and online OTC sales.
Risks and Challenges
- Regulatory restrictions on dextromethorphan sales could limit market size.
- Competition from newer, alternative cough suppressants.
- Price sensitivity in emerging markets may constrain premium pricing.
- Supply chain disruptions affecting raw materials and packaging.
Conclusion: Outlook Summary
The Guaifenesin-DM market remains steady with moderate growth prospects. Price stability is expected, with gradual increases aligned with inflation and regulatory costs. Market expansion hinges on OTC accessibility and consumer health trends.
Key Takeaways
- The global Guaifenesin-DM market was valued at USD 2.5 billion in 2022, with a CAGR of 5% expected through 2027.
- Prices for OTC products range between USD 6 and USD 10 per pack, with incremental increases projected through 2027.
- Competition primarily involves brand-dominant OTC formulations, with private labels holding a significant share.
- Market growth depends on respiratory illness prevalence, OTC regulation, and consumer preferences.
- Price pressure may stem from regulatory restrictions and market competition.
FAQs
1. What are the primary factors influencing Guaifenesin-DM prices?
Manufacturing costs, regulatory compliance, brand positioning, and raw material prices influence retail and wholesale prices.
2. Are there regional differences in Guaifenesin-DM pricing?
Yes, prices are generally higher in Europe and North America due to regulatory costs and brand premiums, while emerging markets have lower prices driven by price-sensitive consumers.
3. How does OTC regulation impact market growth?
Restrictions on sales and packaging can limit access and reduce volume, while liberal regulations promote expansion.
4. What are the main drivers for market entry?
Cost-effective manufacturing, distribution networks, branding, and digital marketing are crucial to entering and capturing market share.
5. How might future regulatory changes affect prices?
Stricter controls on dextromethorphan sales could reduce availability or increase compliance costs, potentially raising retail prices.
References
[1] MarketResearch.com. (2023). Guaifenesin and Dextromethorphan OTC Market Analysis.
[2] IBISWorld. (2023). OTC Pharmaceuticals in North America Industry Report.
[3] Statista. (2023). Over-the-Counter Cough Medicine Market Size & Forecast.
[4] U.S. Food and Drug Administration. (2022). Regulations on Dextromethorphan Sales.
[5] European Medicines Agency. (2022). Guidelines for OTC Cough Medications.
More… ↓
